Core Viewpoint - Kangzheng Pharmaceutical (00867) has seen a stock price increase of over 3%, currently trading at 15.41 HKD, with a transaction volume of 28.85 million HKD, following the announcement of a new drug application for a topical treatment for atopic dermatitis [1] Group 1: Company Developments - On February 24, 2026, Kangzheng Pharmaceutical announced that its subsidiary, Demy Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of phosphor-aluconidine cream for the treatment of mild to moderate atopic dermatitis (AD) [1] - The product is intended for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in children aged 2 years and older and adults, particularly when other topical medications are poorly controlled or not recommended [1] - The NDA has been included in the priority review list by the NMPA due to its compliance with the physiological characteristics of pediatric medications, which is expected to expedite the review process for the AD indication [1] Group 2: Product Milestones - Phosphor-aluconidine cream was approved by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo [1] - The acceptance of the NDA for the AD indication marks a significant milestone for the product, expanding its therapeutic applications into multiple treatment areas [1]
港股异动 | 康哲药业(00867)涨超3% 创新药磷酸芦可替尼乳膏增加AD适应症NDA获受理